FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1182-1183 September 15, 2005 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Mangia, A. PubMed Citation

To the Editor: Mangia and coworkers (June 23 issue)¹ report that the course of combination therapy can be shortened from 24 to 12 weeks with minimal loss of efficacy in patients infected with hepatitis C virus (HCV) genotype 2 or 3 who have early clearance of HCV RNA. Nevertheless, three issues should be considered before these findings in patients in Italy can be extrapolated to U.S. patients.

First, the study used doses of peginterferon alfa-2b (1.0 µg per kilogram of body weight per week) and ribavirin (1000 or 1200 mg daily) that differ from those usually recommended in the United . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.